NXGN · Nextgen Healthcare, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q1 '23 | Q3 '23 | Q2 '23 | Q1 '22 | Q3 '22 | Q2 '22 | Q1 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $176.42M | $178.21M | $153.30M | $161.88M | $159.44M | $146.08M | $149.72M | $149.29M | - | $141.75M |
| Cost of Revenue | $94.80M | $98.39M | $80.05M | $85.35M | $82.58M | $72.74M | $74.20M | $72.70M | - | $70.32M |
| Gross Profit | $81.62M | $79.82M | $73.25M | $76.53M | $76.86M | $73.34M | $75.52M | $76.59M | - | $71.43M |
| R&D | $18.02M | $20.93M | $21.80M | $19.62M | $20.86M | $19.32M | $19.39M | $18.52M | - | $18.20M |
| SG&A | $54.17M | $48.19M | $49.03M | $46.18M | $44.89M | $48.49M | $47.24M | $63.89M | - | $48.97M |
| Total Operating Expenses | $73.56M | $70.75M | $72.06M | $66.96M | $67.57M | $69.61M | $67.51M | $84.48M | - | $70.50M |
| D&A | - | $1.12M | $1.29M | - | - | $2.11M | - | - | - | - |
| Operating Income | $8.06M | $9.07M | $1.19M | $9.56M | $9.29M | $3.73M | $8.01M | ($7.90M) | - | $932.0K |
| Interest Expense | $3.31M | $3.24M | $330.0K | $2.24M | $325.0K | $317.0K | $321.0K | $320.0K | - | $631.0K |
| Income Tax | $1.64M | $2.39M | ($247.0K) | $1.02M | $5.71M | $559.0K | $2.54M | ($1.44M) | - | ($169.0K) |
| Net Income | $5.05M | $6.16M | $1.15M | $7.82M | $13.62M | $2.85M | $5.19M | ($6.77M) | - | $464.0K |
| EPS - Basic | $0.08 | $0.09 | $0.02 | $0.12 | $0.20 | $0.04 | $0.08 | ($0.10) | - | $0.01 |
| EPS - Diluted | $0.07 | $0.09 | $0.02 | $0.12 | $0.20 | $0.04 | $0.08 | ($0.10) | - | $0.01 |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q1 '23 | Q3 '23 | Q2 '23 | Q1 '22 | Q3 '22 | Q2 '22 | Q1 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $53.87M | $70.33M | $98.72M | $241.55M | $70.73M | $59.83M | $49.43M | $75.30M | $73.30M | $89.52M |
| Accounts Receivable | $89.28M | $84.12M | $88.50M | $79.42M | $76.95M | $76.06M | $70.08M | $71.99M | $77.54M | $76.74M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $10.47M | $12.18M | $12.02M | $14.51M | $12.41M | $9.13M | $15.23M | $12.69M | $11.38M | $7.82M |
| Current Assets | $362.80M | $374.73M | $401.82M | $389.64M | $218.15M | $211.57M | $185.74M | $210.71M | $207.64M | $217.35M |
| Total Assets | $857.75M | $868.47M | $896.10M | $871.02M | $627.14M | $627.67M | $605.33M | $635.52M | $644.49M | $655.90M |
| Current Liabilities | $143.88M | $167.84M | $198.11M | $154.20M | $168.61M | $180.86M | $170.41M | $171.18M | $180.63M | $160.04M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $434.48M | $457.95M | $495.67M | $453.26M | $185.30M | $204.60M | $194.19M | $200.25M | $212.84M | $230.19M |
| Stockholders' Equity | $423.27M | $410.52M | $400.44M | $417.76M | $441.84M | $423.08M | $411.14M | $435.28M | $431.64M | $425.71M |
| Retained Earnings | $138.81M | $133.75M | $127.60M | $152.84M | $145.02M | $130.25M | $129.90M | $124.71M | $128.63M | $129.21M |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q1 '23 | Q3 '23 | Q2 '23 | Q1 '22 | Q3 '22 | Q2 '22 | Q1 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($8.10M) | ($4.64M) | - | - | $313.0K | - | - | - | - |
| Investing Cash Flow | - | ($16.69M) | ($9.45M) | - | - | ($6.54M) | - | - | - | - |
| Financing Cash Flow | - | ($3.25M) | ($4.11M) | - | - | ($2.30M) | - | - | - | - |
| CapEx | - | $453.0K | $455.0K | - | - | $1.00M | - | - | - | - |
| Free Cash Flow | - | ($8.55M) | ($5.10M) | - | - | ($689.0K) | - | - | - | - |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q1 '23 | Q3 '23 | Q2 '23 | Q1 '22 | Q3 '22 | Q2 '22 | Q1 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 46.3% | 44.8% | 47.8% | 47.3% | 48.2% | 50.2% | 50.4% | 51.3% | - | 50.4% |
| Operating margin | 4.6% | 5.1% | 0.8% | 5.9% | 5.8% | 2.6% | 5.3% | -5.3% | - | 0.7% |
| EBITDA margin | - | 5.7% | 1.6% | - | - | 4.0% | - | - | - | - |
| Net margin | 2.9% | 3.5% | 0.7% | 4.8% | 8.5% | 1.9% | 3.5% | -4.5% | - | 0.3% |
| Free cash flow margin | - | -4.8% | -3.3% | - | - | -0.5% | - | - | - | - |
| FCF / Net income | - | -1.39 | -4.44 | - | - | -0.24 | - | - | - | - |
| R&D / Revenue | 10.2% | 11.7% | 14.2% | 12.1% | 13.1% | 13.2% | 13.0% | 12.4% | - | 12.8% |
| SG&A / Revenue | 30.7% | 27.0% | 32.0% | 28.5% | 28.2% | 33.2% | 31.6% | 42.8% | - | 34.5% |
| Effective tax rate | 24.5% | 28.0% | -27.4% | 11.5% | 29.5% | 16.4% | 32.8% | - | - | -57.3% |
| Return on assets | 0.6% | 0.7% | 0.1% | 0.9% | 2.2% | 0.5% | 0.9% | -1.1% | - | 0.1% |
| Return on equity | 1.2% | 1.5% | 0.3% | 1.9% | 3.1% | 0.7% | 1.3% | -1.6% | - | 0.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.52 | 2.23 | 2.03 | 2.53 | 1.29 | 1.17 | 1.09 | 1.23 | 1.15 | 1.36 |
| Quick ratio | 2.52 | 2.23 | 2.03 | 2.53 | 1.29 | 1.17 | 1.09 | 1.23 | 1.15 | 1.36 |
| Cash ratio | 0.37 | 0.42 | 0.50 | 1.57 | 0.42 | 0.33 | 0.29 | 0.44 | 0.41 | 0.56 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 2.4x | 2.8x | 3.6x | 4.3x | 28.6x | 11.8x | 24.9x | -24.7x | - | 1.5x |
| Equity multiplier | 2.03 | 2.12 | 2.24 | 2.08 | 1.42 | 1.48 | 1.47 | 1.46 | 1.49 | 1.54 |
| Liabilities / Assets | 0.51 | 0.53 | 0.55 | 0.52 | 0.30 | 0.33 | 0.32 | 0.32 | 0.33 | 0.35 |
| Efficiency | ||||||||||
| Asset turnover | 0.21 | 0.21 | 0.17 | 0.19 | 0.25 | 0.23 | 0.25 | 0.23 | - | 0.22 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 185d | 172d | 211d | 179d | 176d | 190d | 171d | 176d | - | 198d |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 40d | 45d | 55d | 62d | 55d | 46d | 75d | 64d | - | 41d |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 10.6% | 16.2% | 4.9% | 8.1% | 6.8% | - | 5.6% | 6.6% | - | 2.9% |
| Revenue CAGR (3y) | 8.0% | - | 5.4% | 5.5% | 5.9% | - | 4.4% | 4.0% | - | - |
| Revenue CAGR (5y) | 5.9% | - | 2.9% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 6.2% | 9.0% | -0.1% | 1.3% | 0.4% | - | 5.7% | 7.8% | - | 2.6% |
| Operating income growth (YoY) | -13.3% | 661.8% | -68.1% | 19.4% | - | - | 759.2% | - | - | -71.6% |
| Net income growth (YoY) | -62.9% | 436.2% | -59.7% | 50.5% | - | - | 1019.2% | - | - | -89.5% |
| EPS growth (YoY) | -65.0% | 350.0% | -50.0% | 50.0% | - | - | 700.0% | - | - | -85.7% |
| EPS CAGR (3y) | -24.1% | - | - | 19.7% | 30.5% | - | 4.6% | - | - | - |
| EPS CAGR (5y) | -18.9% | - | -12.9% | - | - | -7.8% | 32.0% | - | - | -43.3% |
| FCF growth (YoY) | - | -67.6% | -640.2% | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -4.2% | 2.5% | -5.4% | 1.6% | 1.5% | -2.0% | -3.4% | 3.7% | 6.9% | 6.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2023-03-31.
Product / service
$1.31B totalRecurring Revenue$593.92M · 45.5%
Subscription Services$184.05M · 14.1%
Support And Maintenance$153.52M · 11.8%
Managed Services$129.12M · 9.9%
Transactional And Data Services$127.24M · 9.7%
Software Hardware And Other Non Recurring$59.25M · 4.5%
Other Non Recurring Services$31.39M · 2.4%
Software License And Hardware$27.86M · 2.1%
Peer comparison
Same SIC group: Services-Computer Integrated Systems Design
Comparing NEXTGEN HEALTHCARE against the 5 most active filers in the same SIC group.